nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ABCB1—ovarian cancer	0.271	1	CbGaD
Mefloquine—CYP19A1—Paclitaxel—ovarian cancer	0.0996	0.301	CbGbCtD
Mefloquine—ABCB1—Topotecan—ovarian cancer	0.0426	0.129	CbGbCtD
Mefloquine—ABCB1—Vinorelbine—ovarian cancer	0.03	0.0906	CbGbCtD
Mefloquine—CYP2D6—Vinorelbine—ovarian cancer	0.0283	0.0854	CbGbCtD
Mefloquine—CYP3A4—Topotecan—ovarian cancer	0.0255	0.0771	CbGbCtD
Mefloquine—CYP19A1—follicular fluid—ovarian cancer	0.0225	0.175	CbGeAlD
Mefloquine—ABCB1—Paclitaxel—ovarian cancer	0.0211	0.0637	CbGbCtD
Mefloquine—CYP3A4—Vinorelbine—ovarian cancer	0.018	0.0543	CbGbCtD
Mefloquine—ABCB1—Docetaxel—ovarian cancer	0.0152	0.046	CbGbCtD
Mefloquine—HBA2—oviduct—ovarian cancer	0.0146	0.114	CbGeAlD
Mefloquine—CYP19A1—corpus luteum—ovarian cancer	0.013	0.101	CbGeAlD
Mefloquine—CYP3A4—Paclitaxel—ovarian cancer	0.0126	0.0382	CbGbCtD
Mefloquine—ABCB1—Doxorubicin—ovarian cancer	0.0114	0.0343	CbGbCtD
Mefloquine—CYP2D6—Doxorubicin—ovarian cancer	0.0107	0.0323	CbGbCtD
Mefloquine—CYP19A1—ovarian follicle—ovarian cancer	0.0102	0.079	CbGeAlD
Mefloquine—CYP3A4—Docetaxel—ovarian cancer	0.00913	0.0276	CbGbCtD
Mefloquine—BCHE—diaphragm—ovarian cancer	0.00846	0.0658	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—ovarian cancer	0.0068	0.0206	CbGbCtD
Mefloquine—HBA2—embryo—ovarian cancer	0.00451	0.0351	CbGeAlD
Mefloquine—HBA2—epithelium—ovarian cancer	0.00368	0.0286	CbGeAlD
Mefloquine—HBA1—female reproductive system—ovarian cancer	0.00297	0.0232	CbGeAlD
Mefloquine—HBA1—bone marrow—ovarian cancer	0.00281	0.0219	CbGeAlD
Mefloquine—HBA2—female reproductive system—ovarian cancer	0.00273	0.0213	CbGeAlD
Mefloquine—HBA1—female gonad—ovarian cancer	0.00271	0.0211	CbGeAlD
Mefloquine—HBA2—bone marrow—ovarian cancer	0.00258	0.0201	CbGeAlD
Mefloquine—HBA2—female gonad—ovarian cancer	0.00249	0.0193	CbGeAlD
Mefloquine—HBA1—testis—ovarian cancer	0.0024	0.0187	CbGeAlD
Mefloquine—HBA2—testis—ovarian cancer	0.0022	0.0172	CbGeAlD
Mefloquine—HBA1—lymph node—ovarian cancer	0.00174	0.0135	CbGeAlD
Mefloquine—HBA2—lymph node—ovarian cancer	0.0016	0.0124	CbGeAlD
Mefloquine—ADORA2A—gonad—ovarian cancer	0.00159	0.0124	CbGeAlD
Mefloquine—ADORA2A—female reproductive system—ovarian cancer	0.00142	0.0111	CbGeAlD
Mefloquine—ADORA1—female reproductive system—ovarian cancer	0.00123	0.00955	CbGeAlD
Mefloquine—ADORA2A—testis—ovarian cancer	0.00115	0.00893	CbGeAlD
Mefloquine—ADORA1—vagina—ovarian cancer	0.00111	0.00864	CbGeAlD
Mefloquine—BCHE—myometrium—ovarian cancer	0.00103	0.008	CbGeAlD
Mefloquine—CYP19A1—endometrium—ovarian cancer	0.001	0.00782	CbGeAlD
Mefloquine—ADORA1—testis—ovarian cancer	0.000991	0.00771	CbGeAlD
Mefloquine—ACHE—testis—ovarian cancer	0.000985	0.00766	CbGeAlD
Mefloquine—CYP19A1—gonad—ovarian cancer	0.000932	0.00725	CbGeAlD
Mefloquine—CYP19A1—uterus—ovarian cancer	0.000926	0.00721	CbGeAlD
Mefloquine—CYP19A1—female reproductive system—ovarian cancer	0.000832	0.00648	CbGeAlD
Mefloquine—BCHE—uterine cervix—ovarian cancer	0.0008	0.00623	CbGeAlD
Mefloquine—CYP19A1—female gonad—ovarian cancer	0.000757	0.00589	CbGeAlD
Mefloquine—BCHE—endometrium—ovarian cancer	0.000724	0.00563	CbGeAlD
Mefloquine—ADORA1—lymph node—ovarian cancer	0.000718	0.00559	CbGeAlD
Mefloquine—ACHE—lymph node—ovarian cancer	0.000714	0.00555	CbGeAlD
Mefloquine—CYP19A1—testis—ovarian cancer	0.000672	0.00523	CbGeAlD
Mefloquine—BCHE—uterus—ovarian cancer	0.000667	0.00519	CbGeAlD
Mefloquine—BCHE—female reproductive system—ovarian cancer	0.0006	0.00467	CbGeAlD
Mefloquine—BCHE—bone marrow—ovarian cancer	0.000566	0.00441	CbGeAlD
Mefloquine—BCHE—vagina—ovarian cancer	0.000542	0.00422	CbGeAlD
Mefloquine—ABCB1—myometrium—ovarian cancer	0.00049	0.00381	CbGeAlD
Mefloquine—CYP19A1—lymph node—ovarian cancer	0.000487	0.00379	CbGeAlD
Mefloquine—BCHE—testis—ovarian cancer	0.000484	0.00377	CbGeAlD
Mefloquine—ABCB1—embryo—ovarian cancer	0.000471	0.00367	CbGeAlD
Mefloquine—CYP3A4—female reproductive system—ovarian cancer	0.000404	0.00314	CbGeAlD
Mefloquine—CYP2D6—female reproductive system—ovarian cancer	0.000397	0.00309	CbGeAlD
Mefloquine—ABCB1—epithelium—ovarian cancer	0.000385	0.00299	CbGeAlD
Mefloquine—ABCB1—uterine cervix—ovarian cancer	0.000381	0.00297	CbGeAlD
Mefloquine—ABCB1—decidua—ovarian cancer	0.000363	0.00283	CbGeAlD
Mefloquine—CYP2D6—female gonad—ovarian cancer	0.000361	0.00281	CbGeAlD
Mefloquine—BCHE—lymph node—ovarian cancer	0.000351	0.00273	CbGeAlD
Mefloquine—ABCB1—endometrium—ovarian cancer	0.000345	0.00268	CbGeAlD
Mefloquine—CYP2D6—testis—ovarian cancer	0.000321	0.00249	CbGeAlD
Mefloquine—ABCB1—gonad—ovarian cancer	0.00032	0.00249	CbGeAlD
Mefloquine—ABCB1—uterus—ovarian cancer	0.000318	0.00247	CbGeAlD
Mefloquine—ABCB1—female reproductive system—ovarian cancer	0.000286	0.00222	CbGeAlD
Mefloquine—ABCB1—bone marrow—ovarian cancer	0.00027	0.0021	CbGeAlD
Mefloquine—ABCB1—female gonad—ovarian cancer	0.00026	0.00202	CbGeAlD
Mefloquine—ABCB1—vagina—ovarian cancer	0.000258	0.00201	CbGeAlD
Mefloquine—ABCB1—testis—ovarian cancer	0.000231	0.00179	CbGeAlD
Mefloquine—Hypertension—Paclitaxel—ovarian cancer	0.000201	0.00103	CcSEcCtD
Mefloquine—Alopecia—Docetaxel—ovarian cancer	0.0002	0.00102	CcSEcCtD
Mefloquine—Pruritus—Vinorelbine—ovarian cancer	0.000199	0.00102	CcSEcCtD
Mefloquine—Mental disorder—Docetaxel—ovarian cancer	0.000198	0.00101	CcSEcCtD
Mefloquine—Arthralgia—Paclitaxel—ovarian cancer	0.000198	0.00101	CcSEcCtD
Mefloquine—Chest pain—Paclitaxel—ovarian cancer	0.000198	0.00101	CcSEcCtD
Mefloquine—Myalgia—Paclitaxel—ovarian cancer	0.000198	0.00101	CcSEcCtD
Mefloquine—Anxiety—Paclitaxel—ovarian cancer	0.000197	0.00101	CcSEcCtD
Mefloquine—Erythema—Docetaxel—ovarian cancer	0.000197	0.00101	CcSEcCtD
Mefloquine—Malnutrition—Docetaxel—ovarian cancer	0.000197	0.00101	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000196	0.001	CcSEcCtD
Mefloquine—Nausea—Topotecan—ovarian cancer	0.000196	0.001	CcSEcCtD
Mefloquine—Discomfort—Paclitaxel—ovarian cancer	0.000195	0.001	CcSEcCtD
Mefloquine—Muscular weakness—Epirubicin—ovarian cancer	0.000194	0.000995	CcSEcCtD
Mefloquine—Mood swings—Doxorubicin—ovarian cancer	0.000193	0.000989	CcSEcCtD
Mefloquine—Diarrhoea—Vinorelbine—ovarian cancer	0.000193	0.000986	CcSEcCtD
Mefloquine—Ataxia—Doxorubicin—ovarian cancer	0.000192	0.000981	CcSEcCtD
Mefloquine—Nausea—Melphalan—ovarian cancer	0.000192	0.00098	CcSEcCtD
Mefloquine—Confusional state—Paclitaxel—ovarian cancer	0.000191	0.000978	CcSEcCtD
Mefloquine—Oedema—Paclitaxel—ovarian cancer	0.00019	0.00097	CcSEcCtD
Mefloquine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00019	0.00097	CcSEcCtD
Mefloquine—Muscle spasms—Docetaxel—ovarian cancer	0.000189	0.000968	CcSEcCtD
Mefloquine—Shock—Paclitaxel—ovarian cancer	0.000186	0.000954	CcSEcCtD
Mefloquine—Dizziness—Vinorelbine—ovarian cancer	0.000186	0.000953	CcSEcCtD
Mefloquine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000186	0.000951	CcSEcCtD
Mefloquine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000186	0.00095	CcSEcCtD
Mefloquine—Tachycardia—Paclitaxel—ovarian cancer	0.000185	0.000946	CcSEcCtD
Mefloquine—Skin disorder—Paclitaxel—ovarian cancer	0.000184	0.000942	CcSEcCtD
Mefloquine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000183	0.000938	CcSEcCtD
Mefloquine—Muscular weakness—Doxorubicin—ovarian cancer	0.00018	0.000921	CcSEcCtD
Mefloquine—Vomiting—Vinorelbine—ovarian cancer	0.000179	0.000917	CcSEcCtD
Mefloquine—Rash—Vinorelbine—ovarian cancer	0.000178	0.000909	CcSEcCtD
Mefloquine—Dermatitis—Vinorelbine—ovarian cancer	0.000178	0.000908	CcSEcCtD
Mefloquine—Hypotension—Paclitaxel—ovarian cancer	0.000177	0.000906	CcSEcCtD
Mefloquine—Headache—Vinorelbine—ovarian cancer	0.000177	0.000903	CcSEcCtD
Mefloquine—Syncope—Docetaxel—ovarian cancer	0.000177	0.000903	CcSEcCtD
Mefloquine—Leukopenia—Docetaxel—ovarian cancer	0.000176	0.000902	CcSEcCtD
Mefloquine—Palpitations—Docetaxel—ovarian cancer	0.000174	0.00089	CcSEcCtD
Mefloquine—Loss of consciousness—Docetaxel—ovarian cancer	0.000173	0.000885	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000173	0.000884	CcSEcCtD
Mefloquine—Insomnia—Paclitaxel—ovarian cancer	0.000171	0.000877	CcSEcCtD
Mefloquine—Pneumonia—Epirubicin—ovarian cancer	0.000171	0.000874	CcSEcCtD
Mefloquine—Convulsion—Docetaxel—ovarian cancer	0.000171	0.000873	CcSEcCtD
Mefloquine—Paraesthesia—Paclitaxel—ovarian cancer	0.00017	0.000871	CcSEcCtD
Mefloquine—Hypertension—Docetaxel—ovarian cancer	0.00017	0.00087	CcSEcCtD
Mefloquine—Dyspnoea—Paclitaxel—ovarian cancer	0.000169	0.000865	CcSEcCtD
Mefloquine—Somnolence—Paclitaxel—ovarian cancer	0.000169	0.000862	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000168	0.000862	CcSEcCtD
Mefloquine—Chest pain—Docetaxel—ovarian cancer	0.000168	0.000857	CcSEcCtD
Mefloquine—Arthralgia—Docetaxel—ovarian cancer	0.000168	0.000857	CcSEcCtD
Mefloquine—Myalgia—Docetaxel—ovarian cancer	0.000168	0.000857	CcSEcCtD
Mefloquine—Nausea—Vinorelbine—ovarian cancer	0.000167	0.000856	CcSEcCtD
Mefloquine—ABCB1—lymph node—ovarian cancer	0.000167	0.0013	CbGeAlD
Mefloquine—Renal failure—Epirubicin—ovarian cancer	0.000167	0.000855	CcSEcCtD
Mefloquine—Dyspepsia—Paclitaxel—ovarian cancer	0.000167	0.000854	CcSEcCtD
Mefloquine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000167	0.000852	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000166	0.000852	CcSEcCtD
Mefloquine—Decreased appetite—Paclitaxel—ovarian cancer	0.000165	0.000843	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000164	0.000837	CcSEcCtD
Mefloquine—Fatigue—Paclitaxel—ovarian cancer	0.000163	0.000836	CcSEcCtD
Mefloquine—Sweating—Epirubicin—ovarian cancer	0.000163	0.000833	CcSEcCtD
Mefloquine—Confusional state—Docetaxel—ovarian cancer	0.000162	0.000829	CcSEcCtD
Mefloquine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000161	0.000822	CcSEcCtD
Mefloquine—Oedema—Docetaxel—ovarian cancer	0.000161	0.000822	CcSEcCtD
Mefloquine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000161	0.000822	CcSEcCtD
Mefloquine—Agranulocytosis—Epirubicin—ovarian cancer	0.000159	0.000811	CcSEcCtD
Mefloquine—Pneumonia—Doxorubicin—ovarian cancer	0.000158	0.000809	CcSEcCtD
Mefloquine—Shock—Docetaxel—ovarian cancer	0.000158	0.000809	CcSEcCtD
Mefloquine—Nervous system disorder—Docetaxel—ovarian cancer	0.000158	0.000806	CcSEcCtD
Mefloquine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000157	0.000805	CcSEcCtD
Mefloquine—Tachycardia—Docetaxel—ovarian cancer	0.000157	0.000802	CcSEcCtD
Mefloquine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000156	0.000799	CcSEcCtD
Mefloquine—Skin disorder—Docetaxel—ovarian cancer	0.000156	0.000798	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000156	0.000797	CcSEcCtD
Mefloquine—Bradycardia—Epirubicin—ovarian cancer	0.000155	0.000794	CcSEcCtD
Mefloquine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000155	0.000793	CcSEcCtD
Mefloquine—Renal failure—Doxorubicin—ovarian cancer	0.000155	0.000791	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000154	0.000788	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—ovarian cancer	0.000151	0.000771	CcSEcCtD
Mefloquine—Urticaria—Paclitaxel—ovarian cancer	0.000151	0.00077	CcSEcCtD
Mefloquine—Hypotension—Docetaxel—ovarian cancer	0.00015	0.000768	CcSEcCtD
Mefloquine—Connective tissue disorder—Epirubicin—ovarian cancer	0.00015	0.000767	CcSEcCtD
Mefloquine—Abdominal pain—Paclitaxel—ovarian cancer	0.00015	0.000767	CcSEcCtD
Mefloquine—Body temperature increased—Paclitaxel—ovarian cancer	0.00015	0.000767	CcSEcCtD
Mefloquine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000149	0.000761	CcSEcCtD
Mefloquine—Visual impairment—Epirubicin—ovarian cancer	0.000147	0.000752	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—ovarian cancer	0.000147	0.000751	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000146	0.000749	CcSEcCtD
Mefloquine—Insomnia—Docetaxel—ovarian cancer	0.000145	0.000743	CcSEcCtD
Mefloquine—Paraesthesia—Docetaxel—ovarian cancer	0.000144	0.000738	CcSEcCtD
Mefloquine—Erythema multiforme—Epirubicin—ovarian cancer	0.000144	0.000738	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—ovarian cancer	0.000144	0.000735	CcSEcCtD
Mefloquine—Dyspnoea—Docetaxel—ovarian cancer	0.000143	0.000733	CcSEcCtD
Mefloquine—Somnolence—Docetaxel—ovarian cancer	0.000143	0.000731	CcSEcCtD
Mefloquine—Eye disorder—Epirubicin—ovarian cancer	0.000143	0.000729	CcSEcCtD
Mefloquine—Tinnitus—Epirubicin—ovarian cancer	0.000142	0.000728	CcSEcCtD
Mefloquine—Flushing—Epirubicin—ovarian cancer	0.000142	0.000724	CcSEcCtD
Mefloquine—Cardiac disorder—Epirubicin—ovarian cancer	0.000142	0.000724	CcSEcCtD
Mefloquine—Dyspepsia—Docetaxel—ovarian cancer	0.000141	0.000724	CcSEcCtD
Mefloquine—Decreased appetite—Docetaxel—ovarian cancer	0.00014	0.000715	CcSEcCtD
Mefloquine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00014	0.000714	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000139	0.00071	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000139	0.00071	CcSEcCtD
Mefloquine—Fatigue—Docetaxel—ovarian cancer	0.000139	0.000709	CcSEcCtD
Mefloquine—Angiopathy—Epirubicin—ovarian cancer	0.000138	0.000708	CcSEcCtD
Mefloquine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000137	0.000703	CcSEcCtD
Mefloquine—Chills—Epirubicin—ovarian cancer	0.000137	0.0007	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—ovarian cancer	0.000136	0.000696	CcSEcCtD
Mefloquine—Asthenia—Paclitaxel—ovarian cancer	0.000136	0.000696	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—ovarian cancer	0.000135	0.00069	CcSEcCtD
Mefloquine—Pruritus—Paclitaxel—ovarian cancer	0.000134	0.000686	CcSEcCtD
Mefloquine—Mental disorder—Epirubicin—ovarian cancer	0.000134	0.000684	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—ovarian cancer	0.000133	0.000683	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—ovarian cancer	0.000133	0.000679	CcSEcCtD
Mefloquine—Erythema—Epirubicin—ovarian cancer	0.000133	0.000679	CcSEcCtD
Mefloquine—Feeling abnormal—Docetaxel—ovarian cancer	0.000132	0.000677	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—ovarian cancer	0.000132	0.000675	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—ovarian cancer	0.000132	0.000673	CcSEcCtD
Mefloquine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000131	0.000672	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—ovarian cancer	0.000131	0.00067	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000131	0.00067	CcSEcCtD
Mefloquine—Diarrhoea—Paclitaxel—ovarian cancer	0.00013	0.000664	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—ovarian cancer	0.000128	0.000655	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—ovarian cancer	0.000128	0.000653	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000127	0.000651	CcSEcCtD
Mefloquine—Abdominal pain—Docetaxel—ovarian cancer	0.000127	0.00065	CcSEcCtD
Mefloquine—Body temperature increased—Docetaxel—ovarian cancer	0.000127	0.00065	CcSEcCtD
Mefloquine—Chills—Doxorubicin—ovarian cancer	0.000127	0.000648	CcSEcCtD
Mefloquine—Dizziness—Paclitaxel—ovarian cancer	0.000125	0.000641	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—ovarian cancer	0.000125	0.00064	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—ovarian cancer	0.000125	0.000638	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—ovarian cancer	0.000124	0.000633	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000123	0.00063	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—ovarian cancer	0.000123	0.000629	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—ovarian cancer	0.000123	0.000629	CcSEcCtD
Mefloquine—Agitation—Epirubicin—ovarian cancer	0.000122	0.000624	CcSEcCtD
Mefloquine—Vomiting—Paclitaxel—ovarian cancer	0.000121	0.000617	CcSEcCtD
Mefloquine—Malaise—Epirubicin—ovarian cancer	0.00012	0.000613	CcSEcCtD
Mefloquine—Rash—Paclitaxel—ovarian cancer	0.00012	0.000611	CcSEcCtD
Mefloquine—Dermatitis—Paclitaxel—ovarian cancer	0.000119	0.000611	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—ovarian cancer	0.000119	0.00061	CcSEcCtD
Mefloquine—Syncope—Epirubicin—ovarian cancer	0.000119	0.000609	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—ovarian cancer	0.000119	0.000608	CcSEcCtD
Mefloquine—Headache—Paclitaxel—ovarian cancer	0.000119	0.000608	CcSEcCtD
Mefloquine—Hypersensitivity—Docetaxel—ovarian cancer	0.000118	0.000606	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—ovarian cancer	0.000118	0.000604	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—ovarian cancer	0.000117	0.0006	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—ovarian cancer	0.000117	0.000597	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—ovarian cancer	0.000116	0.000592	CcSEcCtD
Mefloquine—Asthenia—Docetaxel—ovarian cancer	0.000115	0.00059	CcSEcCtD
Mefloquine—Convulsion—Epirubicin—ovarian cancer	0.000115	0.000589	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—ovarian cancer	0.000115	0.000587	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000114	0.000583	CcSEcCtD
Mefloquine—Pruritus—Docetaxel—ovarian cancer	0.000114	0.000582	CcSEcCtD
Mefloquine—Arthralgia—Epirubicin—ovarian cancer	0.000113	0.000578	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—ovarian cancer	0.000113	0.000578	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—ovarian cancer	0.000113	0.000578	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—ovarian cancer	0.000113	0.000578	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—ovarian cancer	0.000113	0.000576	CcSEcCtD
Mefloquine—Nausea—Paclitaxel—ovarian cancer	0.000113	0.000576	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000112	0.000574	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—ovarian cancer	0.000112	0.000571	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—ovarian cancer	0.000111	0.000567	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—ovarian cancer	0.00011	0.000565	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—ovarian cancer	0.00011	0.000564	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—ovarian cancer	0.00011	0.000563	CcSEcCtD
Mefloquine—Diarrhoea—Docetaxel—ovarian cancer	0.00011	0.000562	CcSEcCtD
Mefloquine—Confusional state—Epirubicin—ovarian cancer	0.000109	0.000559	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—ovarian cancer	0.000109	0.000555	CcSEcCtD
Mefloquine—Oedema—Epirubicin—ovarian cancer	0.000108	0.000554	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000108	0.000554	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000108	0.000552	CcSEcCtD
Mefloquine—Shock—Epirubicin—ovarian cancer	0.000107	0.000545	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—ovarian cancer	0.000106	0.000545	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—ovarian cancer	0.000106	0.000544	CcSEcCtD
Mefloquine—Dizziness—Docetaxel—ovarian cancer	0.000106	0.000544	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000106	0.000543	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—ovarian cancer	0.000106	0.000543	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—ovarian cancer	0.000106	0.000541	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—ovarian cancer	0.000105	0.000539	CcSEcCtD
Mefloquine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000105	0.000536	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—ovarian cancer	0.000105	0.000535	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—ovarian cancer	0.000105	0.000535	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—ovarian cancer	0.000105	0.000535	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—ovarian cancer	0.000104	0.000533	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000104	0.000531	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—ovarian cancer	0.000103	0.000529	CcSEcCtD
Mefloquine—Vomiting—Docetaxel—ovarian cancer	0.000102	0.000523	CcSEcCtD
Mefloquine—Rash—Docetaxel—ovarian cancer	0.000101	0.000518	CcSEcCtD
Mefloquine—Hypotension—Epirubicin—ovarian cancer	0.000101	0.000518	CcSEcCtD
Mefloquine—Dermatitis—Docetaxel—ovarian cancer	0.000101	0.000518	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—ovarian cancer	0.000101	0.000517	CcSEcCtD
Mefloquine—Headache—Docetaxel—ovarian cancer	0.000101	0.000515	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—ovarian cancer	0.0001	0.000513	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.0001	0.000513	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	9.87e-05	0.000505	CcSEcCtD
Mefloquine—Shock—Doxorubicin—ovarian cancer	9.86e-05	0.000505	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—ovarian cancer	9.83e-05	0.000503	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—ovarian cancer	9.82e-05	0.000502	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—ovarian cancer	9.8e-05	0.000501	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—ovarian cancer	9.79e-05	0.000501	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—ovarian cancer	9.74e-05	0.000498	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—ovarian cancer	9.73e-05	0.000498	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—ovarian cancer	9.69e-05	0.000496	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—ovarian cancer	9.66e-05	0.000494	CcSEcCtD
Mefloquine—Somnolence—Epirubicin—ovarian cancer	9.63e-05	0.000493	CcSEcCtD
Mefloquine—Nausea—Docetaxel—ovarian cancer	9.54e-05	0.000488	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—ovarian cancer	9.54e-05	0.000488	CcSEcCtD
Mefloquine—Decreased appetite—Epirubicin—ovarian cancer	9.42e-05	0.000482	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—ovarian cancer	9.37e-05	0.000479	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—ovarian cancer	9.36e-05	0.000479	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—ovarian cancer	9.34e-05	0.000478	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	9.13e-05	0.000467	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—ovarian cancer	9.07e-05	0.000464	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—ovarian cancer	9e-05	0.000461	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—ovarian cancer	8.94e-05	0.000457	CcSEcCtD
Mefloquine—Feeling abnormal—Epirubicin—ovarian cancer	8.93e-05	0.000457	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—ovarian cancer	8.91e-05	0.000456	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—ovarian cancer	8.86e-05	0.000453	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—ovarian cancer	8.83e-05	0.000452	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—ovarian cancer	8.72e-05	0.000446	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	8.66e-05	0.000443	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—ovarian cancer	8.64e-05	0.000442	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—ovarian cancer	8.61e-05	0.00044	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—ovarian cancer	8.57e-05	0.000438	CcSEcCtD
Mefloquine—Body temperature increased—Epirubicin—ovarian cancer	8.57e-05	0.000438	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—ovarian cancer	8.26e-05	0.000423	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—ovarian cancer	8.2e-05	0.000419	CcSEcCtD
Mefloquine—Hypersensitivity—Epirubicin—ovarian cancer	7.98e-05	0.000408	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—ovarian cancer	7.97e-05	0.000408	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—ovarian cancer	7.93e-05	0.000406	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—ovarian cancer	7.93e-05	0.000406	CcSEcCtD
Mefloquine—Asthenia—Epirubicin—ovarian cancer	7.77e-05	0.000398	CcSEcCtD
Mefloquine—Pruritus—Epirubicin—ovarian cancer	7.67e-05	0.000392	CcSEcCtD
Mefloquine—Diarrhoea—Epirubicin—ovarian cancer	7.41e-05	0.000379	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—ovarian cancer	7.39e-05	0.000378	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—ovarian cancer	7.19e-05	0.000368	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—ovarian cancer	7.17e-05	0.000367	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—ovarian cancer	7.09e-05	0.000363	CcSEcCtD
Mefloquine—Vomiting—Epirubicin—ovarian cancer	6.89e-05	0.000353	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—ovarian cancer	6.86e-05	0.000351	CcSEcCtD
Mefloquine—Rash—Epirubicin—ovarian cancer	6.83e-05	0.00035	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—ovarian cancer	6.83e-05	0.000349	CcSEcCtD
Mefloquine—Headache—Epirubicin—ovarian cancer	6.79e-05	0.000347	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—ovarian cancer	6.63e-05	0.000339	CcSEcCtD
Mefloquine—Nausea—Epirubicin—ovarian cancer	6.44e-05	0.000329	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—ovarian cancer	6.38e-05	0.000326	CcSEcCtD
Mefloquine—Rash—Doxorubicin—ovarian cancer	6.32e-05	0.000323	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—ovarian cancer	6.32e-05	0.000323	CcSEcCtD
Mefloquine—Headache—Doxorubicin—ovarian cancer	6.28e-05	0.000321	CcSEcCtD
Mefloquine—Nausea—Doxorubicin—ovarian cancer	5.96e-05	0.000305	CcSEcCtD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	3.08e-05	0.000417	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—YAP1—ovarian cancer	3.07e-05	0.000416	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PGR—ovarian cancer	3.06e-05	0.000414	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.04e-05	0.000412	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	3.02e-05	0.000409	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PPP2R1A—ovarian cancer	2.98e-05	0.000404	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—YAP1—ovarian cancer	2.98e-05	0.000404	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PIK3CD—ovarian cancer	2.97e-05	0.000403	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—IL6—ovarian cancer	2.97e-05	0.000402	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.95e-05	0.0004	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.94e-05	0.000399	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.91e-05	0.000394	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CG—ovarian cancer	2.88e-05	0.000389	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—PIK3CB—ovarian cancer	2.85e-05	0.000386	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PARP1—ovarian cancer	2.84e-05	0.000385	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—MAPK1—ovarian cancer	2.81e-05	0.00038	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—AKT1—ovarian cancer	2.8e-05	0.000379	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CXCL8—ovarian cancer	2.74e-05	0.000371	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—AKT1—ovarian cancer	2.74e-05	0.000371	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—FASN—ovarian cancer	2.72e-05	0.000369	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL6ST—ovarian cancer	2.72e-05	0.000368	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—SLC5A5—ovarian cancer	2.68e-05	0.000363	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.68e-05	0.000363	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.67e-05	0.000362	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—IL2—ovarian cancer	2.62e-05	0.000355	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CG—ovarian cancer	2.61e-05	0.000354	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.59e-05	0.000351	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PIK3CB—ovarian cancer	2.59e-05	0.000351	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—SLC2A1—ovarian cancer	2.59e-05	0.000351	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.53e-05	0.000343	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—MMP2—ovarian cancer	2.53e-05	0.000343	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—HRAS—ovarian cancer	2.53e-05	0.000342	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CD—ovarian cancer	2.53e-05	0.000342	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—FASN—ovarian cancer	2.5e-05	0.000339	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.49e-05	0.000337	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CXCL8—ovarian cancer	2.49e-05	0.000337	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CYP1B1—ovarian cancer	2.48e-05	0.000336	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYTB—ovarian cancer	2.48e-05	0.000336	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.48e-05	0.000336	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—SLC5A5—ovarian cancer	2.46e-05	0.000334	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—FASN—ovarian cancer	2.43e-05	0.000329	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.43e-05	0.000329	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.41e-05	0.000326	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—SLC5A5—ovarian cancer	2.39e-05	0.000324	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL2—ovarian cancer	2.38e-05	0.000322	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—SLC2A1—ovarian cancer	2.38e-05	0.000322	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NME2—ovarian cancer	2.37e-05	0.000321	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TERT—ovarian cancer	2.37e-05	0.000321	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.37e-05	0.00032	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.34e-05	0.000317	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYTB—ovarian cancer	2.34e-05	0.000317	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.33e-05	0.000315	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—SLC2A1—ovarian cancer	2.31e-05	0.000313	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PPP2R1A—ovarian cancer	2.3e-05	0.000312	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CD—ovarian cancer	2.3e-05	0.000311	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.28e-05	0.000309	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CYP1B1—ovarian cancer	2.28e-05	0.000309	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.26e-05	0.000306	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—MMP2—ovarian cancer	2.26e-05	0.000306	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—HRAS—ovarian cancer	2.26e-05	0.000305	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CYP1B1—ovarian cancer	2.21e-05	0.0003	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CB—ovarian cancer	2.2e-05	0.000298	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PPP2R1A—ovarian cancer	2.2e-05	0.000298	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CAV1—ovarian cancer	2.19e-05	0.000297	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.19e-05	0.000297	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—BRIP1—ovarian cancer	2.17e-05	0.000294	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PPP1CC—ovarian cancer	2.17e-05	0.000294	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CXCL8—ovarian cancer	2.12e-05	0.000287	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ESR1—ovarian cancer	2.11e-05	0.000286	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CXCL8—ovarian cancer	2.1e-05	0.000285	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL6ST—ovarian cancer	2.08e-05	0.000282	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.06e-05	0.000279	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PPP1CC—ovarian cancer	2.04e-05	0.000277	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—BRIP1—ovarian cancer	2.04e-05	0.000277	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ABCB1—ovarian cancer	2.04e-05	0.000277	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—IL2—ovarian cancer	2.02e-05	0.000274	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PPP2R1A—ovarian cancer	2.02e-05	0.000274	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.01e-05	0.000273	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—TYMS—ovarian cancer	2.01e-05	0.000272	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CB—ovarian cancer	2e-05	0.000271	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—APC—ovarian cancer	2e-05	0.000271	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CG—ovarian cancer	2e-05	0.000271	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—NRAS—ovarian cancer	2e-05	0.00027	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PPP2R1A—ovarian cancer	1.96e-05	0.000266	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.95e-05	0.000265	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.95e-05	0.000264	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CTNNB1—ovarian cancer	1.94e-05	0.000263	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CXCL8—ovarian cancer	1.92e-05	0.00026	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—MAPK3—ovarian cancer	1.91e-05	0.000259	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.9e-05	0.000257	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ABCB1—ovarian cancer	1.88e-05	0.000254	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CXCL8—ovarian cancer	1.88e-05	0.000254	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.86e-05	0.000251	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.86e-05	0.000251	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—TYMS—ovarian cancer	1.84e-05	0.00025	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL2—ovarian cancer	1.84e-05	0.000249	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TERT—ovarian cancer	1.83e-05	0.000248	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ABCB1—ovarian cancer	1.82e-05	0.000247	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—MAPK1—ovarian cancer	1.82e-05	0.000246	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—EGFR—ovarian cancer	1.82e-05	0.000246	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—TYMS—ovarian cancer	1.79e-05	0.000242	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CD—ovarian cancer	1.76e-05	0.000238	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.75e-05	0.000237	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—PIK3CA—ovarian cancer	1.74e-05	0.000236	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CTNNB1—ovarian cancer	1.73e-05	0.000235	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—KRAS—ovarian cancer	1.72e-05	0.000233	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CAV1—ovarian cancer	1.69e-05	0.000229	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ESR1—ovarian cancer	1.63e-05	0.000221	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CAV1—ovarian cancer	1.62e-05	0.000219	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.61e-05	0.000218	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6ST—ovarian cancer	1.61e-05	0.000217	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PIK3CA—ovarian cancer	1.58e-05	0.000214	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.56e-05	0.000211	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ERBB2—ovarian cancer	1.55e-05	0.00021	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.55e-05	0.000209	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CG—ovarian cancer	1.54e-05	0.000209	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—APC—ovarian cancer	1.54e-05	0.000209	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—NRAS—ovarian cancer	1.54e-05	0.000209	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MTOR—ovarian cancer	1.53e-05	0.000207	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CB—ovarian cancer	1.53e-05	0.000207	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYTB—ovarian cancer	1.53e-05	0.000207	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CAV1—ovarian cancer	1.49e-05	0.000201	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—MAPK3—ovarian cancer	1.48e-05	0.0002	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CG—ovarian cancer	1.47e-05	0.000199	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CXCL8—ovarian cancer	1.47e-05	0.000199	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—HRAS—ovarian cancer	1.46e-05	0.000198	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—YAP1—ovarian cancer	1.45e-05	0.000197	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CAV1—ovarian cancer	1.44e-05	0.000195	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1B—ovarian cancer	1.44e-05	0.000195	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—AKT1—ovarian cancer	1.42e-05	0.000192	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.42e-05	0.000192	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CASP3—ovarian cancer	1.41e-05	0.000191	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL2—ovarian cancer	1.41e-05	0.00019	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—MAPK1—ovarian cancer	1.41e-05	0.00019	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—EGFR—ovarian cancer	1.41e-05	0.00019	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL6—ovarian cancer	1.4e-05	0.000189	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.38e-05	0.000187	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—YAP1—ovarian cancer	1.37e-05	0.000186	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—ovarian cancer	1.37e-05	0.000186	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CTNNB1—ovarian cancer	1.36e-05	0.000184	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CD—ovarian cancer	1.36e-05	0.000184	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CG—ovarian cancer	1.35e-05	0.000183	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	1.34e-05	0.000182	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.34e-05	0.000181	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.34e-05	0.000181	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MMP9—ovarian cancer	1.33e-05	0.00018	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—ovarian cancer	1.33e-05	0.00018	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTEN—ovarian cancer	1.32e-05	0.000179	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.32e-05	0.000178	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CG—ovarian cancer	1.31e-05	0.000178	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CD—ovarian cancer	1.3e-05	0.000175	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AKT1—ovarian cancer	1.29e-05	0.000175	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CA—ovarian cancer	1.22e-05	0.000165	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ERBB2—ovarian cancer	1.2e-05	0.000162	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—ovarian cancer	1.19e-05	0.000162	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CD—ovarian cancer	1.19e-05	0.000161	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—FASN—ovarian cancer	1.19e-05	0.000161	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—STAT3—ovarian cancer	1.18e-05	0.00016	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CB—ovarian cancer	1.18e-05	0.00016	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MTOR—ovarian cancer	1.18e-05	0.00016	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NRAS—ovarian cancer	1.18e-05	0.00016	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.17e-05	0.000158	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CD—ovarian cancer	1.16e-05	0.000156	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL8—ovarian cancer	1.14e-05	0.000154	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MAPK3—ovarian cancer	1.13e-05	0.000153	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CB—ovarian cancer	1.13e-05	0.000153	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—HRAS—ovarian cancer	1.13e-05	0.000153	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.13e-05	0.000153	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—FASN—ovarian cancer	1.12e-05	0.000151	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1B—ovarian cancer	1.11e-05	0.00015	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.1e-05	0.000149	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MYC—ovarian cancer	1.1e-05	0.000149	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AKT1—ovarian cancer	1.1e-05	0.000149	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CASP3—ovarian cancer	1.09e-05	0.000147	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL2—ovarian cancer	1.09e-05	0.000147	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.08e-05	0.000146	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL6—ovarian cancer	1.08e-05	0.000146	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MAPK1—ovarian cancer	1.08e-05	0.000146	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EGFR—ovarian cancer	1.08e-05	0.000146	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.06e-05	0.000144	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—ovarian cancer	1.06e-05	0.000143	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CTNNB1—ovarian cancer	1.05e-05	0.000142	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CB—ovarian cancer	1.04e-05	0.00014	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MMP9—ovarian cancer	1.03e-05	0.000139	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTEN—ovarian cancer	1.02e-05	0.000138	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.02e-05	0.000138	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—ovarian cancer	1.02e-05	0.000138	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CB—ovarian cancer	1.01e-05	0.000136	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AKT1—ovarian cancer	9.96e-06	0.000135	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTEN—ovarian cancer	9.75e-06	0.000132	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PPP2R1A—ovarian cancer	9.58e-06	0.00013	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CA—ovarian cancer	9.33e-06	0.000126	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—ovarian cancer	9.22e-06	0.000125	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—STAT3—ovarian cancer	9.13e-06	0.000124	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NRAS—ovarian cancer	9.11e-06	0.000123	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	9.03e-06	0.000122	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—ovarian cancer	9.03e-06	0.000122	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—YAP1—ovarian cancer	8.96e-06	0.000121	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTEN—ovarian cancer	8.96e-06	0.000121	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TYMS—ovarian cancer	8.74e-06	0.000118	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK3—ovarian cancer	8.73e-06	0.000118	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTEN—ovarian cancer	8.7e-06	0.000118	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HRAS—ovarian cancer	8.63e-06	0.000117	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MYC—ovarian cancer	8.49e-06	0.000115	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCB1—ovarian cancer	8.38e-06	0.000114	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK1—ovarian cancer	8.3e-06	0.000112	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGFR—ovarian cancer	8.3e-06	0.000112	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL6—ovarian cancer	8.26e-06	0.000112	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TYMS—ovarian cancer	8.23e-06	0.000111	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—ovarian cancer	7.84e-06	0.000106	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AKT1—ovarian cancer	7.62e-06	0.000103	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—FASN—ovarian cancer	7.31e-06	9.9e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CA—ovarian cancer	7.2e-06	9.76e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	7.19e-06	9.73e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CAV1—ovarian cancer	7.04e-06	9.53e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—ovarian cancer	6.97e-06	9.44e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	6.94e-06	9.4e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CA—ovarian cancer	6.88e-06	9.32e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HRAS—ovarian cancer	6.67e-06	9.03e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	6.66e-06	9.01e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CAV1—ovarian cancer	6.63e-06	8.98e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CG—ovarian cancer	6.41e-06	8.68e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6—ovarian cancer	6.38e-06	8.64e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CA—ovarian cancer	6.32e-06	8.56e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CA—ovarian cancer	6.14e-06	8.31e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	6.04e-06	8.18e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.9e-06	7.99e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AKT1—ovarian cancer	5.89e-06	7.97e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CD—ovarian cancer	5.64e-06	7.63e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AKT1—ovarian cancer	5.62e-06	7.61e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.48e-06	7.42e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TYMS—ovarian cancer	5.38e-06	7.29e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.31e-06	7.19e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKT1—ovarian cancer	5.17e-06	7e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKT1—ovarian cancer	5.02e-06	6.79e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.91e-06	6.65e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.63e-06	6.27e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CAV1—ovarian cancer	4.34e-06	5.87e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTEN—ovarian cancer	4.25e-06	5.75e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTEN—ovarian cancer	4e-06	5.42e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.95e-06	5.35e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.47e-06	4.7e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.03e-06	4.1e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CA—ovarian cancer	3e-06	4.06e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.82e-06	3.82e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTEN—ovarian cancer	2.62e-06	3.54e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKT1—ovarian cancer	2.45e-06	3.31e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKT1—ovarian cancer	2.31e-06	3.12e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.85e-06	2.5e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKT1—ovarian cancer	1.51e-06	2.04e-05	CbGpPWpGaD
